Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLCA. Aguilar, M. Cobo, A. Azkarate,A. Calles, M. Gonzalez-Cao, A. Cantero, J. Terrasa,R. Alvarez,M. A. Molina, R. RosellJOURNAL OF THORACIC ONCOLOGY（2023）引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
